$231.18
Insights on Iqvia Holdings Inc.
Revenue is down for the last 2 quarters, 3.90B → 3.74B (in $), with an average decrease of 4.3% per quarter
Netprofit is down for the last 2 quarters, 469.0M → 288.0M (in $), with an average decrease of 38.6% per quarter
In the last 1 year, Agilent Technologies Inc. has given 19.4% return, outperforming this stock by 1.1%
In the last 3 years, Thermo Fisher Scientific, Inc. has given 19.8% return, outperforming this stock by 19.5%
0.0%
Downside
Day's Volatility :1.96%
Upside
1.96%
27.58%
Downside
52 Weeks Volatility :36.03%
Upside
11.67%
Period | Iqvia Holdings Inc. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -1.52% | 0.5% | 5.9% |
6 Months | 12.61% | 14.1% | 17.5% |
1 Year | 18.28% | 11.9% | 26.3% |
3 Years | 0.26% | 18.7% | 28.5% |
Market Capitalization | 42.1B |
Book Value | $34.82 |
Earnings Per Share (EPS) | 7.31 |
PE Ratio | 31.63 |
PEG Ratio | 1.33 |
Wall Street Target Price | 271.24 |
Profit Margin | 9.01% |
Operating Margin TTM | 13.94% |
Return On Assets TTM | 5.03% |
Return On Equity TTM | 22.11% |
Revenue TTM | 15.1B |
Revenue Per Share TTM | 82.42 |
Quarterly Revenue Growth YOY | 2.3% |
Gross Profit TTM | 5.0B |
EBITDA | 2.8B |
Diluted Eps TTM | 7.31 |
Quarterly Earnings Growth YOY | 0.02 |
EPS Estimate Current Year | 11.08 |
EPS Estimate Next Year | 12.47 |
EPS Estimate Current Quarter | 2.48 |
EPS Estimate Next Quarter | 2.66 |
What analysts predicted
Upside of 17.33%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 10.4B | ↑ 6.91% |
Net Income | 259.0M | ↓ 80.21% |
Net Profit Margin | 2.49% | ↓ 10.95% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 11.1B | ↑ 6.49% |
Net Income | 191.0M | ↓ 26.25% |
Net Profit Margin | 1.72% | ↓ 0.77% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 11.4B | ↑ 2.44% |
Net Income | 279.0M | ↑ 46.07% |
Net Profit Margin | 2.46% | ↑ 0.74% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 13.9B | ↑ 22.14% |
Net Income | 966.0M | ↑ 246.24% |
Net Profit Margin | 6.96% | ↑ 4.5% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 14.4B | ↑ 3.86% |
Net Income | 1.1B | ↑ 12.94% |
Net Profit Margin | 7.57% | ↑ 0.61% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 15.0B | ↑ 4.13% |
Net Income | 1.4B | ↑ 24.47% |
Net Profit Margin | 9.05% | ↑ 1.48% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↑ 4.97% |
Net Income | 227.0M | ↓ 19.79% |
Net Profit Margin | 6.07% | ↓ 1.87% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↓ 2.33% |
Net Income | 289.0M | ↑ 27.31% |
Net Profit Margin | 7.91% | ↑ 1.84% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↑ 2.08% |
Net Income | 297.0M | ↑ 2.77% |
Net Profit Margin | 7.97% | ↑ 0.06% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↑ 0.21% |
Net Income | 303.0M | ↑ 2.02% |
Net Profit Margin | 8.11% | ↑ 0.14% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.9B | ↑ 4.63% |
Net Income | 469.0M | ↑ 54.79% |
Net Profit Margin | 12.0% | ↑ 3.89% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↓ 4.32% |
Net Income | 288.0M | ↓ 38.59% |
Net Profit Margin | 7.7% | ↓ 4.3% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 22.5B | ↓ 0.85% |
Total Liabilities | 15.6B | ↑ 8.42% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 23.3B | ↑ 3.11% |
Total Liabilities | 17.0B | ↑ 8.93% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 24.6B | ↑ 5.65% |
Total Liabilities | 18.3B | ↑ 7.63% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 24.7B | ↑ 0.51% |
Total Liabilities | 18.6B | ↑ 1.99% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 25.3B | ↑ 2.62% |
Total Liabilities | 19.6B | ↑ 4.96% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 26.7B | ↑ 5.3% |
Total Liabilities | 20.6B | ↑ 5.09% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 25.3B | ↑ 4.6% |
Total Liabilities | 19.6B | ↑ 3.69% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 25.7B | ↑ 1.59% |
Total Liabilities | 19.8B | ↑ 1.2% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 26.0B | ↑ 1.15% |
Total Liabilities | 20.3B | ↑ 2.43% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 26.0B | ↓ 0.23% |
Total Liabilities | 20.2B | ↓ 0.57% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 26.7B | ↑ 2.71% |
Total Liabilities | 20.6B | ↑ 1.97% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 26.6B | ↓ 0.4% |
Total Liabilities | 20.2B | ↓ 1.65% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3B | ↑ 29.28% |
Investing Cash Flow | -810.0M | ↓ 31.93% |
Financing Cash Flow | -452.0M | ↑ 527.78% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.4B | ↑ 13.0% |
Investing Cash Flow | -1.2B | ↑ 46.91% |
Financing Cash Flow | -276.0M | ↓ 38.94% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.0B | ↑ 38.25% |
Investing Cash Flow | -796.0M | ↓ 33.11% |
Financing Cash Flow | -217.0M | ↓ 21.38% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.9B | ↑ 50.18% |
Investing Cash Flow | -2.1B | ↑ 164.2% |
Financing Cash Flow | -1.2B | ↑ 469.12% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.3B | ↓ 23.18% |
Investing Cash Flow | -2.0B | ↓ 4.61% |
Financing Cash Flow | -329.0M | ↓ 73.36% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 560.0M | ↓ 5.41% |
Investing Cash Flow | -2.0B | ↑ 179.78% |
Financing Cash Flow | -193.0M | ↓ 23.11% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 417.0M | ↓ 25.54% |
Investing Cash Flow | -222.0M | ↓ 88.93% |
Financing Cash Flow | 87.0M | ↓ 145.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 402.0M | ↓ 3.6% |
Investing Cash Flow | -596.0M | ↑ 168.47% |
Financing Cash Flow | 95.0M | ↑ 9.2% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 583.0M | ↑ 45.02% |
Investing Cash Flow | -1.4B | ↑ 133.39% |
Financing Cash Flow | -144.0M | ↓ 251.58% |
Sell
Neutral
Buy
Iqvia Holdings Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Iqvia Holdings Inc. | 1.77% | 12.61% | 18.28% | 0.26% | 72.95% |
Idexx Laboratories, Inc. | 13.74% | 14.91% | 10.44% | 3.54% | 118.66% |
Agilent Technologies Inc. | 16.45% | 35.31% | 19.43% | 19.79% | 123.75% |
Thermo Fisher Scientific, Inc. | 9.93% | 26.92% | 13.71% | 30.95% | 126.43% |
Danaher Corp. | 12.46% | 25.95% | 17.39% | 6.35% | 103.96% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Iqvia Holdings Inc. | 31.63 | 31.63 | 1.33 | 11.08 | 0.22 | 0.05 | NA | 34.82 |
Idexx Laboratories, Inc. | 52.37 | 52.37 | 4.75 | 11.04 | 0.72 | 0.23 | NA | 18.93 |
Agilent Technologies Inc. | 36.92 | 36.92 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 38.3 | 38.3 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 119.24 |
Danaher Corp. | 48.51 | 48.51 | 3.13 | 7.61 | 0.08 | 0.04 | 0.0 | 72.16 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Iqvia Holdings Inc. | Buy | $42.1B | 72.95% | 31.63 | 9.01% |
Idexx Laboratories, Inc. | Buy | $44.7B | 118.66% | 52.37 | 23.26% |
Agilent Technologies Inc. | Buy | $45.2B | 123.75% | 36.92 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $227.9B | 126.43% | 38.3 | 14.2% |
Danaher Corp. | Buy | $196.2B | 103.96% | 48.51 | 18.55% |
Vanguard Group Inc
BlackRock Inc
Harris Associates L.P.
State Street Corporation
AllianceBernstein L.P.
Morgan Stanley - Brokerage Accounts
quintiles and imshealth have merged together to form the new quintilesims. each wanting to bring something new to customers, we deliver integrated information and technology solutions to drive healthcare forward. quintilesims has approximately 50,000 employees conducting operations in more than 100 countries, dedicated to helping our clients improve their clinical, scientific and commercial results. as a global leader in protecting individual patient privacy, quintilesims uses healthcare data to deliver critical, real-world disease and treatment insights. to learn more, visit www.quintilesims.com
Organization | Iqvia Holdings Inc. |
Employees | 87000 |
CEO | Mr. Ari Bousbib |
Industry | Health Services |
Celanese Corporation
$231.18
-1.63%
Restaurant Brands International
$231.18
-1.63%
Rio Tinto Plc
$231.18
-1.63%
Thomson Reuters Corp.
$231.18
-1.63%
Zimmer Biomet Holdings, Inc.
$231.18
-1.63%
Xylem Inc.
$231.18
-1.63%
Ishares Msci Emr Mrk Ex Chna
$231.18
-1.63%
Natwest Group Plc
$231.18
-1.63%
Ppg Industries Inc.
$231.18
-1.63%